Source: BusinessWire Bristol-Myers Squibb Company (NYSE:BMY) and Celgene Corporation (NASDAQ:CELG) today announced that they have entered into a definitive merger agreement under which Bristol-Myers Squibb will acquire Celgene in a cash and stock transaction with an equity value of approximately $74 billion. Under the terms of the agreement, Celgene shareholders…...
UnitedHealth buys Genoa Healthcare, adding more than 400 pharmacies to its PBM
Source: FierceHealthcare With new competitors closing in, UnitedHealth is bolstering its defenses by purchasing Genoa Healthcare, the fifth-largest pharmacy chain in the country with 435 locations. Genoa—which also offers telepsychiatry services and medication management for behavioral health patients—will be absorbed by UnitedHealth’s pharmacy benefit manager OptumRx. According to its website,…...
"You are simply the best at what you do. What a powerful resource and great business partner." - Director, U.S. Training and Leadership Development, Biopharmaceuticals...
Allergan preludes major selloffs with $650M Almirall dermatology sale
Source: FiercePharma Allergan, which is shopping assets to help turn its stock price around, has taken its first small step into selloff land. Spain’s Almirall said Friday it had agreed to pick up a portfolio of medical dermatology products from the Dublin drugmaker for up to $650 million in cash,…...
Bayer sells prescription dermatology brands to Denmark’s Leo Pharma
Source: Reuters FRANKFURT (Reuters) - Bayer has agreed to sell its established prescription dermatology brands to Denmark’s Leo Pharma, as the German drugmaker focuses on integrating seed maker Monsanto and on bolstering its drug development pipeline. The portfolio to be sold includes prescription skin creams against acne, fungal skin infections…...
Sienna Biopharmaceuticals Successfully Completes Maximal Use Safety Study Of SNA-120 In Patients With Itch Associated With Psoriasis
Source: Sienna Biopharmaceuticals Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA), a clinical-stage medical dermatology and aesthetics company, today announced results from a Phase 1b maximal use (MUse) pharmacokinetic (PK) and safety study of SNA-120 (pegcantratinib), a Phase 2b drug candidate being evaluated as a topical, nonsteroidal therapy to treat itch (pruritus) associated with psoriasis.…...
Cassiopea Announces Very Positive Top-Line Phase 3 Results For Winlevi® (Clascoterone) Cream In Treating Acne
Source: Cassiopea Lainate, Italy – 10 July 2018 - Cassiopea SpA (SIX: SKIN), a clinical-stage specialty pharmaceutical company focused on developing and commercializing innovative and differentiated medical dermatology products, today announced that top line results from two pivotal phase 3 clinical trials for its topical anti-androgen Winlevi® cream 1% (Clascoterone) demonstrated…...
"Working with Rick has been a pleasure. He truly looks at how to best put a person in a place to be successful and land a position which is one or two levels up from where they are currently at based on their skill sets. He continuously searches for opportunities…...
"I've had direct experience in working with QFR as well as other firms who provide recruiting services for sales leadership roles. QFR's approach with their clients as well as the candidates they represent is second to none. They are thorough, detail-oriented, and passionate about building great relationships that lead to…...
"I wanted to share my experience with QFR and specifically Stacey Healy, one of the recruiters. I have had the opportunity to work with a handful of recruiters throughout my professional career and she is, hands down the best! She was professional, thorough, patient, and a fantastic coach through out the…...